Telehealth firms have sought to cash in on the popularity of GLP-1 drugs for weight loss, but a hefty new entrant could prove a bigger windfall for Novo and Lilly in obesity.
‘Outdated notions’ holding back use of effective obesity drugs: report
As Novo Nordisk and other firms gear up to promote a new class of obesity drugs, success depends on marketers helping separate medical fact from TikTok fiction.
Queen Latifah and Novo Nordisk destigmatize obesity